Year-end Sale % OFF 
Abstract
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease,whose exact pathogenesis is not fully clear as yet.The abnormal activation of B cells plays an important role in the development of SLE,and B cell-activating factor (BAFF) is critical for the abnormal activation of B cells.Belimumab is a human monoclonal antibody which can selectively recognize and block soluble BAFF.The efficacy and safety of belimumab have been confirmed for the treatment of SLE in randomized,double-blind,large-scale clinical trials.As a biological agent with high efficacy,few side effects and high tolerability,belimumab is a promising drug for SLE. Key words: Lupus erythematosus, systemic; Belimumab; Molecular targeted therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Dermatology and Venereology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
